JP2024504370A - 慢性痒疹の治療 - Google Patents

慢性痒疹の治療 Download PDF

Info

Publication number
JP2024504370A
JP2024504370A JP2023544302A JP2023544302A JP2024504370A JP 2024504370 A JP2024504370 A JP 2024504370A JP 2023544302 A JP2023544302 A JP 2023544302A JP 2023544302 A JP2023544302 A JP 2023544302A JP 2024504370 A JP2024504370 A JP 2024504370A
Authority
JP
Japan
Prior art keywords
amino acid
antibody
kit
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504370A5 (https=
Inventor
アラン ホーリー ブレット
ゴールドステイン ジョエル
Original Assignee
セルデックス セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルデックス セラピューティクス，インコーポレーテッド filed Critical セルデックス セラピューティクス，インコーポレーテッド
Publication of JP2024504370A publication Critical patent/JP2024504370A/ja
Publication of JP2024504370A5 publication Critical patent/JP2024504370A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023544302A 2021-01-22 2022-01-21 慢性痒疹の治療 Pending JP2024504370A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163140621P 2021-01-22 2021-01-22
US63/140,621 2021-01-22
US202163238688P 2021-08-30 2021-08-30
US63/238,688 2021-08-30
PCT/US2022/013380 WO2022159744A1 (en) 2021-01-22 2022-01-21 Treatment of chronic prurigo

Publications (2)

Publication Number Publication Date
JP2024504370A true JP2024504370A (ja) 2024-01-31
JP2024504370A5 JP2024504370A5 (https=) 2025-01-28

Family

ID=82549848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544302A Pending JP2024504370A (ja) 2021-01-22 2022-01-21 慢性痒疹の治療

Country Status (6)

Country Link
US (1) US20240109961A1 (https=)
EP (1) EP4281113A4 (https=)
JP (1) JP2024504370A (https=)
AU (1) AU2022210696A1 (https=)
CA (1) CA3207110A1 (https=)
WO (1) WO2022159744A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504706A (ja) * 2021-01-22 2024-02-01 セルデックス セラピューティクス，インコーポレーテッド 抗ｋｉｔ抗体及びその使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250726A1 (en) * 2024-05-30 2025-12-04 Celldex Therapeutics, Inc. Anti-kit antibody dosing and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534052A (ja) * 2006-04-24 2009-09-24 アムジェン インコーポレイテッド ヒト化ｃ−Ｋｉｔ抗体
JP2015531752A (ja) * 2012-07-25 2015-11-05 コルタン ファーマシューティカルス，インコーポレーテッド 抗ｋｉｔ抗体及びその使用
JP2017517568A (ja) * 2014-05-23 2017-06-29 コルタン ファーマシューティカルス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009534052A (ja) * 2006-04-24 2009-09-24 アムジェン インコーポレイテッド ヒト化ｃ−Ｋｉｔ抗体
JP2015531752A (ja) * 2012-07-25 2015-11-05 コルタン ファーマシューティカルス，インコーポレーテッド 抗ｋｉｔ抗体及びその使用
JP2017517568A (ja) * 2014-05-23 2017-06-29 コルタン ファーマシューティカルス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504706A (ja) * 2021-01-22 2024-02-01 セルデックス セラピューティクス，インコーポレーテッド 抗ｋｉｔ抗体及びその使用

Also Published As

Publication number Publication date
AU2022210696A1 (en) 2023-09-07
EP4281113A4 (en) 2024-11-20
WO2022159744A1 (en) 2022-07-28
CA3207110A1 (en) 2022-07-28
EP4281113A1 (en) 2023-11-29
US20240109961A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
JP7854003B2 (ja) 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用
US20240117057A1 (en) Anti-kit antibodies and uses thereof
JP6926138B2 (ja) 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
KR20140148411A (ko) 항-cd19 항체를 이용한 다발성 경화증의 치료
US20240109961A1 (en) Treatment of chronic prurigo
IL323100A (en) Antibodies against stem cell factor (SCF) and thymic lymphopoietin (TSLP) and bispecific constructs
CN117136070A (zh) 抗-kit抗体及其用途
CN117120089A (zh) 慢性痒疹的治疗
US20260055193A1 (en) Anti-kit antibody formulations and methods
US20240392005A1 (en) Pd-1/tigit binding proteins for cancer treatment
WO2025250726A1 (en) Anti-kit antibody dosing and methods
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260326